Gennex Laboratories Ltd
Incorporated in 1995, Gennex Laboratories Ltd manufactures Bulk Drugs and Intermediaries[1]
- Market Cap ₹ 387 Cr.
- Current Price ₹ 17.0
- High / Low ₹ 22.5 / 10.8
- Stock P/E 23.5
- Book Value ₹ 8.21
- Dividend Yield 0.00 %
- ROCE 13.0 %
- ROE 10.2 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 59.3% CAGR over last 5 years
- Debtor days have improved from 55.0 to 37.5 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 23.6%
- Company has a low return on equity of 9.80% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| 42 | 44 | 56 | 56 | 60 | 61 | 66 | 87 | 138 | 148 | |
| 37 | 42 | 52 | 52 | 53 | 56 | 61 | 70 | 121 | 126 | |
| Operating Profit | 5 | 2 | 4 | 3 | 7 | 5 | 5 | 17 | 17 | 22 |
| OPM % | 11% | 5% | 7% | 6% | 11% | 9% | 7% | 20% | 12% | 15% |
| 0 | 1 | 1 | 1 | 0 | 1 | 4 | 5 | 10 | 6 | |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 |
| Profit before tax | 3 | 1 | 3 | 3 | 5 | 5 | 6 | 16 | 21 | 22 |
| Tax % | 13% | 42% | 26% | 27% | 20% | 23% | 23% | 20% | 15% | |
| 3 | 1 | 2 | 2 | 4 | 4 | 5 | 13 | 18 | 19 | |
| EPS in Rs | 0.14 | 0.04 | 0.12 | 0.10 | 0.21 | 0.21 | 0.28 | 0.58 | 0.80 | 0.71 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 20% |
| 3 Years: | 31% |
| TTM: | 43% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 59% |
| 3 Years: | 67% |
| TTM: | 13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 36% |
| 3 Years: | 41% |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | 10% |
| Last Year: | 10% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 18 | 23 | 23 |
| Reserves | 18 | 19 | 21 | 23 | 27 | 31 | 62 | 148 | 164 |
| 4 | 2 | 5 | 5 | 7 | 10 | 1 | 6 | 10 | |
| 14 | 16 | 13 | 16 | 12 | 14 | 51 | 54 | 59 | |
| Total Liabilities | 49 | 50 | 52 | 57 | 59 | 68 | 132 | 230 | 256 |
| 16 | 16 | 16 | 15 | 14 | 14 | 74 | 56 | 60 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 |
| Investments | 7 | 7 | 7 | 7 | 7 | 7 | 0 | 0 | 0 |
| 26 | 28 | 29 | 35 | 38 | 48 | 59 | 172 | 191 | |
| Total Assets | 49 | 50 | 52 | 57 | 59 | 68 | 132 | 230 | 256 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| -0 | 3 | 2 | -2 | -1 | 12 | 24 | -47 | -11 | |
| -1 | -1 | -1 | -0 | -0 | -2 | -38 | 19 | 1 | |
| 1 | -2 | 1 | -0 | 2 | -2 | 21 | 74 | 5 | |
| Net Cash Flow | -0 | 0 | 2 | -2 | 0 | 8 | 6 | 46 | -5 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 90 | 87 | 68 | 41 | 55 | 67 | 52 | 75 | 37 |
| Inventory Days | 43 | 31 | 57 | 78 | 50 | 72 | 139 | 184 | 133 |
| Days Payable | 139 | 161 | 88 | 86 | 59 | 72 | 63 | 111 | 49 |
| Cash Conversion Cycle | -7 | -43 | 38 | 34 | 46 | 67 | 129 | 148 | 122 |
| Working Capital Days | 74 | 75 | 56 | 87 | 108 | 87 | 23 | 255 | 214 |
| ROCE % | 6% | 11% | 8% | 14% | 12% | 11% | 14% | 13% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
13 Oct - With reference to the captioned subject matter, pursuant to Regulation 74(5) of SEBI (DP) Regulations, 2018, we hereby submit the certificate received from M/s R&D …
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
1 Oct - Sept 30, 2025 e-AGM: all five resolutions approved; reappointment and appointments ratified, ~31.19M votes (99.99% favor).
- Shareholder Meeting / Postal Ballot-Outcome of AGM 30 Sep
- Closure of Trading Window 23 Sep
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
8 Sep - Newspaper publication of AGM Notice and e-Voting related instructions advertisement published in Business Standard and Saksham (Local) on September 06, 2025 for the 40th Annual …
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
GLL is an ISO 9001:2008, TUV, ISO 14001 and OSHAS 18000 certified vertically integrated Active Pharmaceutical Ingredient manufacturer & exporter of Bulk Drugs, Intermediates and Biotech Products in the form of Expectorants,
Muscle Relaxants, Analgesic and Anti Fungal, etc.